Login to Your Account



Allergy Trial Hits Snafu; Expensive Delay Expected

By Nuala Moran


Wednesday, August 1, 2007
Allergy Therapeutics plc will have to conduct a new U.S. trial of its hay fever allergy vaccine at an additional cost of £10 million (US$20.3 million) after one subject suffered an adverse reaction, causing the FDA to put the trial on hold. This also will delay the launch of the product by 12 months. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription